The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of…
Oxford, UK – 13 December 2021: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, today announces that it has signed a new…
Oxford Biomedica Announces that Boehringer Ingelheim has Exercised Option Relating to a Novel Gene Therapy Treatment for Cystic Fibrosis Oxford, UK – 19 October 2021: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica”…
The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of…
Oxford Biomedica delivers record first half results Oxford, UK – 22 September 2021: Oxford Biomedica plc (“Oxford Biomedica” or “the Group”) (LSE: OXB), a leading gene and cell therapy group,…
London, UK – 1 September 2021: Oxford Biomedica plc (LSE:OXB), a leading gene and cell therapy group, will be announcing its interim results for the six months ended 30 June…
Oxford, UK – 15 July, 2021: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, is pleased to announce that Dr. Michael Hayden…
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of…
London, UK – 27 April 2021: Oxford Biomedica plc (“Oxford Biomedica”, “the Company” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, gives notice that copies of the…
Oxford Biomedica plcPreliminary results for the year ended 31 December 2020 Saving Lives Oxford, UK – 15 April 2021: Oxford Biomedica plc (LSE: OXB), (“OXB” or “the Group”), a leading…
Oxford, UK – 6 April, 2021: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, announced today that it has signed a new…
Oxford, UK – 3 February, 2021: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, today announces two changes to the Group’s Board…